Mirati Therapeutics, Inc. Profile Avatar - Palmy Investing

Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…
Biotechnology
US, San Diego [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

Searching for a Dividend Aristocrat? Sign Up to view the entire dividend history of Mirati Therapeutics, Inc.

Growth Rates
0.00% YoY
0.00% 3Yr
0.00% 5Yr
0.00% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
- -% Yield
0.00% Payout Ratio